Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02607683Phase 2Completed

Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)

Role: lead

NCT01990326Phase 2Suspended

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

Role: lead

NCT02230761Phase 2Completed

Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

Role: lead

NCT01723241Phase 1Completed

Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers

Role: lead

NCT02647853Phase 1Completed

Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers

Role: lead

NCT02607670Phase 2Unknown

Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds

Role: lead

NCT02609763Completed

Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale

Role: lead

All 7 trials loaded